Progressive Supranuclear Palsy (PSP) is a progressive 4R tauopathy for which no FDA-approved disease-modifying therapies currently exist[@boxer2017]. This page provides a comprehensive treatment guide covering symptomatic pharmacotherapy, emerging disease-modifying approaches, and multidisciplinary management strategies for patients with PSP.
PSP, first described by Steele, Richardson, and Olszewski in 1964, is characterized by the accumulation of abnormal tau protein in the basal ganglia, brainstem, and cerebellar structures[1]. The classic Richardson's syndrome (PSP-RS) presents with vertical supranuclear gaze palsy, early postural instability with falls, and frontal cognitive dysfunction. Variant phenotypes include PSP-Parkinsonism (PSP-P), PSP with pure akinesia with gait freezing (PSP-PAGF), and corticobasal syndrome (CBS)[2].
Treatment of PSP requires a multimodal approach combining:
Levodopa remains the first-line pharmacological trial for motor symptoms in PSP, though efficacy is limited compared to Parkinson's disease[1:1]. Approximately 20-30% of patients, particularly those with PSP-P phenotype, show modest transient benefit.
| Medication | Mechanism | Typical Dosing | Evidence Level | Clinical Notes |
|---|---|---|---|---|
| Levodopa/Carbidopa | Dopamine precursor | 100-1000 mg/day | Limited | Trial in all patients; declare non-response after adequate trial |
| Amantadine | NMDA antagonist + dopamine release | 100-200 mg BID | Moderate | May improve rigidity and gait freezing; monitor for confusion[3] |
| Pramipexole | D2/D3 agonist | 0.375-1.5 mg/day | Weak | Impulse control side effects may limit use |
| Rotigotine | D1/D2 agonist | 1-8 mg/24h patch | Weak | Transdermal option for dysphagia |
Levodopa Trial Protocol: Initiate at 25/100 mg three times daily, titrate to maximum tolerated dose (typically 600-1000 mg/day of levodopa) over 4-6 weeks. Assess response using UPDRS motor scores. If no objective improvement after adequate trial, discontinue to avoid adverse effects.
Amantadine Use: Consider amantadine 100-200 mg twice daily for patients with prominent akinesia, rigidity, or gait freezing[3:1]. Side effects include confusion, hallucinations, peripheral edema, and livedo reticularis. Use cautiously in elderly patients.
Botulinum toxin injections are first-line for focal dystonia symptoms in PSP[4][5]:
Retrocollis (neck extension dystonia):
Blepharospasm (involuntary eye closure):
Eyelid-opening apraxia:
Sialorrhea (excessive drooling):
Limb dystonia:
Neuropsychiatric disturbances are common in PSP and significantly impact quality of life[6]:
| Symptom | First-Line Treatment | Second-Line | Key Considerations |
|---|---|---|---|
| Depression | Sertraline 50-200 mg/day | Citalopram 10-20 mg/day | SSRIs preferred; avoid TCAs due to anticholinergic effects |
| Apathy | Methylphenidate 5-20 mg/day | Modafinil 100-200 mg/day | Common and disabling; differentiate from depression |
| Pseudobulbar affect | Dextromethorphan/quinidine (Nuedexta) | SSRIs | FDA-approved for pseudobulbar affect |
| Anxiety | SSRIs | Short-term low-dose benzodiazepines | Fall risk with benzodiazepines |
| Insomnia | Sleep hygiene + melatonin 3-5 mg | Low-dose trazodone 25-50 mg | Avoid anticholinergics and long-acting benzodiazepines |
| REM sleep behavior disorder | Melatonin 3-12 mg at bedtime | Clonazepam 0.25-1 mg | Melatonin preferred due to fall risk |
Apathy in PSP: Apathy is particularly common and often undertreated. It may be difficult to distinguish from depression. Methylphenidate requires monitoring for cardiac side effects. Modafinil may be better tolerated in some patients.
Pseudobulbar Affect: The combination of dextromethorphan/quinidine (Nuedexta) is the only FDA-approved treatment for pseudobulbar affect. Quinidine is a CYP2D6 inhibitor - check for drug interactions.
Cognitive impairment, particularly frontal/executive dysfunction, is a core feature of PSP[7]. Cholinergic deficits in the pedunculopontine nucleus (PPN) and cortical regions contribute to cognitive impairment:
Vertical supranuclear gaze palsy is the hallmark of PSP. Management strategies:
Multiple monoclonal antibodies targeting tau are in clinical development for PSP[8][9]:
| Agent | Company | Target | Phase | Status |
|---|---|---|---|---|
| Semorinemab (RO7105685) | Genentech/Roche | N-terminal tau | Phase 2 | Completed - no significant efficacy in PSP-RS |
| Tilavonemab (ABBV-8E12) | AbbVie | Aggregated tau | Phase 2 | Completed - no efficacy in PSP-RS[10] |
| Bepranemab (UCB0107) | UCB Pharma | Mid-domain tau | Phase 1/2 | Ongoing |
| E2814 | Eisai | Microtubule-binding region | Phase 1/2 | DIAN-TU platform |
| JNJ-63733657 | Janssen | pT217 tau | Phase 2 | Active in AD, potential for PSP |
The failure of tilavonemab and semorinemab in PSP trials highlights the challenge of treating an established neurodegenerative process. Future approaches may need to target earlier disease stages or different tau conformations.
ASOs offer the advantage of reducing tau production at the source, potentially preventing the spread of pathology. However, delivery to the CNS requires intrathecal administration.
The glycogen synthase kinase-3β (GSK-3β) is a key kinase responsible for tau phosphorylation at multiple disease-relevant epitopes[11]:
Agents that enhance autophagy-mediated tau clearance:
These interventions have the strongest mechanistic rationale and clinical evidence:
Mediterranean/MIND Diet (Score: 64/80)
The highest-ranked intervention combines Mediterranean and DASH dietary patterns, emphasizing:
PREDIMED-Plus and Rush MIND studies demonstrate sustained cognitive benefit. For PSP patients with dysphagia, adapt to texture-modified preparations as needed.
Structured Exercise (Score: 62/80)
Physical exercise is the single most impactful non-pharmacological intervention:
Evidence supports benefit in gait speed, balance, fall frequency, and quality of life.
Rasagiline (Score: 60/80)
MAO-B inhibitor with potential neuroprotective properties:
Rapamycin (Score: 57/80)
mTORC1 inhibitor that restores autophagy-mediated tau clearance:
Alpha-Lipoic Acid (Score: 56/80)
Mitochondrial antioxidant targeting Complex I deficiency:
TUDCA/UDCA (Score: 56/80)
Bile acid chemical chaperones:
Low-Dose Lithium (Score: 55/80)
GSK-3β inhibitor that directly reduces tau phosphorylation:
Spermidine (Score: 55/80)
Natural polyamine that induces autophagy:
| Intervention | Score | Mechanism | Typical Dosing |
|---|---|---|---|
| Senolytics (D+Q) | 54/80 | Clear senescent glia, reduce SASP | Intermittent 2-day courses monthly |
| NAD+ Precursors | 53/80 | Mitochondrial NAD+ repletion | NMN 500 mg or NR 300 mg/day |
| Melatonin | 53/80 | Antioxidant, tau kinase inhibition | 3-5 mg at bedtime |
| Urolithin A | 53/80 | Mitophagy induction via PINK1/Parkin | 500-1000 mg/day |
| Methylene Blue | 50/80 | Tau aggregation inhibitor | 8-16 mg/day (NOT with SSRIs) |
| CoQ10 | 48/80 | Complex I electron carrier | 400-1200 mg/day ubiquinol |
| Omega-3 DHA/EPA | 48/80 | SPM biosynthesis, membrane integrity | 2-4 g/day EPA+DHA |
| Curcumin | 40/80 | Tau anti-aggregation, NF-κB suppression | Bioavailable formulation required |
Physical therapy is the single most impactful intervention for functional outcomes in PSP:
Gait and Balance Training:
Fall Prevention:
Neck and Spinal Exercises:
Aerobic Conditioning:
Dysphagia develops in most PSP patients and is the leading cause of death via aspiration pneumonia[13]:
Optimal PSP management requires a coordinated team approach[6:1]:
| Team Member | Role | Recommended Frequency |
|---|---|---|
| Movement disorder neurologist | Diagnosis, pharmacotherapy, clinical trial enrollment | Every 3-6 months |
| Physical therapist | Gait, balance, exercise program | Weekly → biweekly |
| Occupational therapist | ADL adaptation, home safety, assistive devices | Monthly → as needed |
| Speech-language pathologist | Voice therapy, swallowing assessment, AAC | Weekly → monthly |
| Neuropsychologist | Cognitive assessment, behavioral strategies | Every 6-12 months |
| Social worker | Care coordination, financial planning, support resources | As needed |
| Palliative care specialist | Symptom management, advance directives, end-of-life planning | From diagnosis onward |
| Dietitian/nutritionist | Weight monitoring, diet modification, PEG timing | Every 3-6 months |
Tracking disease progression in PSP requires multimodal assessment[14]:
| Domain | Assessment Tool | Frequency |
|---|---|---|
| Motor | PSP Rating Scale (PSPRS), Timed Up and Go | Every 3-6 months |
| Cognitive | MoCA, Frontal Assessment Battery | Every 6 months |
| Falls | Fall calendar, injurious fall tracking | Monthly |
| Dysphagia | VFSS, weight tracking | Every 6-12 months |
| Mood | GDS, NPI | Every 6 months |
| Quality of life | PSP-QoL, PDQ-39 | Every 6-12 months |
The field of PSP therapeutics is actively evolving. Key resources for finding trials:
Future PSP treatment will likely incorporate:
Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration. Arch Neurol. 1964. ↩︎ ↩︎
Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy. Neurology. 1996. ↩︎
Chen L, Chen Y, Wang J, et al. Efficacy and safety of amantadine in progressive supranuclear palsy. Park Relat Disord. 2019. ↩︎ ↩︎
Scelzo E, Lozano AM, Bhatt M, et al. Botulinum toxin in PSP blepharospasm and limb dystonia. J Neurol. 2003. ↩︎
Parks A, Tripathi M, Raza MH, et al. Botulinum toxin for treatment of dystonia in neurodegenerative disorders. Toxins. 2021. ↩︎
Golbe LI. Progressive supranuclear palsy. Semin Neurol. 2014. ↩︎ ↩︎
Lees AJ, Morris HR, Wight J, et al. What features improve the accuracy of the clinical diagnosis of PSP?. Mov Disord. 2012. ↩︎
Shoeibi A, Olfati N, Litvan I. Frontrunner in translation: progressive supranuclear palsy. Front Neurol. 2019. ↩︎
Stamelou M, Höglinger GU. Novel therapeutics in progressive supranuclear palsy. Curr Opin Neurol. 2021. ↩︎
Höglinger GU, Litvan I, Mendonca N, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2 randomised placebo-controlled trial. Lancet Neurol. 2021. ↩︎
Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A. 2005. ↩︎ ↩︎
Tolosa E, Litvan I, Höglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014. ↩︎
Müller J, Wenning GK, Verny M, et al. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol. 2001. ↩︎
Respondek G, Stamelou M, Höglinger GU. Current and future therapeutic approaches to PSP. Expert Rev Neurother. 2019. ↩︎